Sponsored by WuXi Advanced Therapies 7 Feb 2023 Streamlining CAR-T cell therapy manufacturing: a platform approach …organization to deliver the CAR gene to a patient’s T cells and expand them into the final CAR-T therapy product, increasing manufacturing efficiency. Test-taking cells Once the CAR-T therapy has… February 7, 2023 - 7 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 5 Jun 2024 Evolving standards of care: new treatments for cervical cancer …a treatment-related death caused by immune-mediated colitis, an adverse event linked to immune checkpoint inhibitors that affects the digestive system. The researchers involved in the trial stated that both the… June 5, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2024 Eight areas where gene therapy shines …with its investigational treatment, AMT-130. This therapy employs an AAV vector to deliver microRNAs that silence the mutant huntingtin gene, reducing the production of the toxic protein responsible for neuronal… November 21, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 9 Apr 2025 Cystic fibrosis: is the next blockbuster a gene therapy? …of salt in and out of the cells in the body. As a result of the mutation, salt becomes trapped in the cells. Without the flow of salt, cell surfaces… April 9, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 Mar 2025 Nine biotechs thriving in Seattle in 2025 …Receptor (RACR) technology, which employs rapamycin to support the survival of the CAR-T cells. Lastly, its TUMORTAG tags the tumors so that CAR-T cells can identify the targets more easily,… March 13, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2017 Resilient Tumor Cells Drive Breast Cancer Relapse in Mice …metabolism in resilient cells to breast cancer relapse. “Our results suggest that residual cells retain an “oncogenic memory”; that could be exploited to develop drugs against breast cancer recurrence,” said… May 25, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2025 ASCO 2025: key highlights in cancer therapeutics …the tumor cell and absent from healthy cells so that the T cells are directed at the tumor. The target of CER-1236, TIM-4-L, is really unusual in that healthy cells… June 4, 2025 - 18 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2024 Eight companies spearheading Philadelphia’s biotech industry …and CAR-monocytes. These engineered cells leverage the innate and adaptive immune responses to target and destroy cancer cells, particularly in solid tumors. Unlike traditional CAR-T therapies that face challenges in… May 21, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2017 This Dutch Company is Upgrading ADCs for Immunotherapy …‘immunotoxins’ that act synergistically to kill their target cells is what makes it special — it’s only the second immunotoxin combination ever to be tested in the clinic. How does… March 13, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2018 French Scientists Find a Weak Spot in HIV-Infected Cells …the French scientists unveiled that HIV prefers to infect those T cells with higher metabolic activity, making them a promising target to get rid of the latent virus. T cells… December 21, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Mar 2024 7 oncolytic virus companies you should know about …(T-SIGn) platform to deliver novel immunotherapeutic proteins, biomolecules, and transgene combinations to treat solid tumors. The company’s portfolio is made up of solid tumor-targeted T-SIGn therapeutics that aim to enable… March 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Interview 22 Jan 2018 Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target …cells and seed them, thereby scaling up that material to billions of adipose stem cells. These are the cells that we then put in vials to treat inflammatory issues. What’s… January 22, 2018 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email